In general, BioApex plans to take its pipeline compounds through Proof of Concept studies at which point it will seek strong industry partners to share its late stage development risk. We are an innovative partner for companies with unique program specific expertise in aging, inflammatory diseases and cancer.

Our in-house library of heterocyclic compounds contains several lead chemotypes with high selectivity for different protein kinases including CDKs, Aurora, GSK-3, Bcr-Abl and other kinases. We have established an access programme around our proprietary kinase inhibitor library to promote the development of selected compounds in anti-aging, anti-inflammatory, anticancer, other non-oncological indications. We offer collaborations in these areas.

Please contact: biopex@atlas.cz

Olchemim, s.r.o.

On May 31, 2009, we signed a license agreement with OlChemIm regarding production of purine derivatives of plant hormone origin.

Palacký University, Olomouc, Czech Republic & Institute of Organic Chemistry, Warsaw, Poland

On March 30, 2009, we signed a collaborative agreement with Palacký University and the Warsaw Institute of Organic Chemistry regarding the development of new anti-melanoma compounds.

Palacký University, Olomouc, Czech Republic

On February 27, 2009, we signed a cooperative research and joint commercialization agreement with the Palacký University regarding drugs combining anticancer and antiviral activities.

Uniwersytet w Białymstoku

On February 9, 2009, we signed a joint patent agreement with UwB regarding development of anticancer compounds derived from new saponins.

Palacký University, Olomouc, Czech Republic & PSORTECH DERMAL SCIENCES LLC Santa Fe, USA

On May 9, 2013, we signed a joint cooperative research and commercialization agreement with the Palacký University and PSORTECH DERMAL SCIENCES LLC regarding antipsoriatic compounds derived from natural plant hormone cytokinin.